Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285)

Henan Lingrui Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	3,560	3,307	2,998	2,690	2,328	2,154
Other Revenue	3.98	3.98	3.44	3.48	3.44	3.35
Revenue	3,564	3,311	3,002	2,694	2,332	2,157
Revenue Growth (YoY)	10.28%	10.31%	11.45%	15.52%	8.09%	5.06%
Cost of Revenue	942.2	888.53	837.53	707.97	547.68	493.33
Gross Profit	2,622	2,423	2,164	1,986	1,784	1,664
Selling, General & Admin	1,746	1,675	1,608	1,483	1,342	1,217
Research & Development	117.69	109.65	125.07	86.21	97.76	78.67
Other Operating Expenses	40.11	44.84	40.54	37.4	28.4	33.45
Operating Expenses	1,913	1,834	1,775	1,609	1,468	1,335
Operating Income	708.96	588.93	389.07	376.45	316.2	328.69
Interest Expense	-	-0.2	-1.14	-1.9	-1.1	-9.96
Interest & Investment Income	63.09	55.87	86.61	43.03	57.89	12.36
Currency Exchange Gain (Loss)	-0.01	-0.01	0	-0	0	-0
Other Non Operating Income (Expenses)	2.05	-1.69	-1.75	-1.7	7.08	-0.29
EBT Excluding Unusual Items	774.09	642.9	472.79	415.88	380.07	330.8
Impairment of Goodwill	-	-	-	-	-0.5	-
Gain (Loss) on Sale of Investments	-3.58	0.12	5.93	0.05	-0.05	-9.99
Gain (Loss) on Sale of Assets	-0.68	-0.63	-0.1	-20.32	-2.95	-0.4
Asset Writedown	-2.05	-1.83	-	-	-27.8	-
Other Unusual Items	12.49	12.49	38.42	17.74	15.43	20.89
Pretax Income	780.27	653.04	517.03	413.35	364.2	341.28
Income Tax Expense	104.43	84.93	51.73	50.85	39.82	48.14
Earnings From Continuing Operations	675.84	568.12	465.3	362.5	324.38	293.15
Minority Interest in Earnings	-0.04	-0.01	-0	-0.96	1.11	1.29
Net Income	675.8	568.11	465.3	361.54	325.49	294.44
Net Income to Common	675.8	568.11	465.3	361.54	325.49	294.44
Net Income Growth	28.44%	22.09%	28.70%	11.08%	10.55%	21.04%
Shares Outstanding (Basic)	560	561	557	556	568	575
Shares Outstanding (Diluted)	562	566	568	567	568	575
Shares Change (YoY)	-0.51%	-0.30%	0.26%	-0.24%	-1.22%	-2.60%
EPS (Basic)	1.21	1.01	0.84	0.65	0.57	0.51
EPS (Diluted)	1.20	1.00	0.82	0.64	0.57	0.51
EPS Growth	29.11%	22.47%	28.37%	11.34%	11.91%	24.27%
Free Cash Flow	610.92	792.23	807.92	768.78	378.71	391.12
Free Cash Flow Per Share	1.09	1.40	1.42	1.36	0.67	0.68
Dividend Per Share	0.800	0.800	0.600	0.500	0.400	0.300
Dividend Growth	33.33%	33.33%	20.00%	25.00%	33.33%	100.00%
Gross Margin	73.56%	73.17%	72.10%	73.72%	76.51%	77.13%
Operating Margin	19.89%	17.78%	12.96%	13.98%	13.56%	15.24%
Profit Margin	18.96%	17.16%	15.50%	13.42%	13.96%	13.65%
Free Cash Flow Margin	17.14%	23.92%	26.91%	28.54%	16.24%	18.13%
EBITDA	785.89	664.74	463.4	447.63	384.66	396.26
EBITDA Margin	22.05%	20.07%	15.44%	16.62%	16.50%	18.37%
D&A For EBITDA	76.92	75.81	74.33	71.18	68.46	67.57
EBIT	708.96	588.93	389.07	376.45	316.2	328.69
EBIT Margin	19.89%	17.78%	12.96%	13.98%	13.56%	15.24%
Effective Tax Rate	13.38%	13.00%	10.01%	12.30%	10.93%	14.11%
Revenue as Reported	3,564	3,311	3,002	2,694	2,332	2,157
Advertising Expenses	-	265.07	295.91	-	356.56	236.93

Source: S&P Capital IQ. Standard template. Financial Sources.